Polygenic Risk Scores in Prostate Cancer Risk Assessment and Screening

Urol Clin North Am. 2021 Aug;48(3):387-399. doi: 10.1016/j.ucl.2021.03.007. Epub 2021 Jun 10.ABSTRACTMore than 40% of the risk of developing prostate cancer (PCa) is from genetic factors. Genome-wide association studies have led to the discovery of more than 140 variants associated with PCa risk. Polygenic risk scores (PRS) generated using these variants show promise in identifying individuals at much higher (and lower) lifetime risk than the average man. PCa PRS also improve the predictive value of prostate-specific antigen screening, may inform the age for starting PCa screening, and are informative for development of more aggressive tumors. Despite the promise, few clinical trials have evaluated the benefit of PCa PRS for clinical care.PMID:34210493 | DOI:10.1016/j.ucl.2021.03.007
Source: The Urologic Clinics of North America - Category: Urology & Nephrology Authors: Source Type: research